panflu Stats

[Mixin]

Xcellerex, Inc., along with three collaborators, has been awarded an $11M Phase 2 contract by the Defense Threat Reduction Agency to develop technology for accelerated monoclonal antibody and vaccine manufacturing.

Xcellerex, which serves as the prime contractor, is collaborating with Dowpharmasm, a business unit of the Dow Chemical Company, Biopharm Services, and deltaDOT. The team combines Xcellerex’s microbial PDMax™ high speed process development and FlexFactory™ single-use manufacturing technologies with Dowpharma’s Pfēnex Expression TechnologyTM and deltaDOT’s Peregrine® label free CE-based analytical technology. The team is guided by BioPharm Services systems integration, data management/process economics, and simulated event modeling technology.

http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20090324005676&newsLang=en
_________________
https://twitter.com/mixin1771